Evidence map›Paper›PMID 35879192›Full record

ArticleCancer science2022

The first Japanese biobank of patient-derived pediatric acute lymphoblastic leukemia xenograft models.

Kuniaki Tanaka, Itaru Kato, Yuu Dobashi, Jun-Ichi Imai, Takashi Mikami, Hirohito Kubota, Hiroo Ueno, Mamoru Ito, Seishi Ogawa, Tatsutoshi Nakahata and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. [Optimized treatment of childhood B-lineage acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Kuniaki TanakaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Itaru KatoDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-2932-4960
Yuu DobashiMedical-Industrial Translational Research Center, Fukushima Medical University, Fukushima, Japan.
Jun-Ichi ImaiMedical-Industrial Translational Research Center, Fukushima Medical University, Fukushima, Japan.
Takashi MikamiDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hirohito KubotaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroo UenoDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Mamoru ItoCentral Institute for Experimental Animals, Kawasaki, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tatsutoshi NakahataCentral Institute for Experimental Animals, Kawasaki, Japan.
Junko TakitaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hidemi ToyodaJapan Children's Cancer Group, Relapsed ALL Committee, Nagoya, Japan.
Chitose OgawaJapan Children's Cancer Group, Relapsed ALL Committee, Nagoya, Japan.
Souichi AdachiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shinya WatanabeMedical-Industrial Translational Research Center, Fukushima Medical University, Fukushima, Japan.
Hiroaki GotoJapan Children's Cancer Group, Relapsed ALL Committee, Nagoya, Japan.
Kyoto University · JPChildren's Oncology Group · CHFukushima Medical University · JPCentral Institute for Experimental Animals · JP

Funding

grant for cancer research by Kyoto preventive medical centerTakeda Science Foundation
6 · The paper itself

Abstract

A lack of practical resources in Japan has limited preclinical discovery and testing of therapies for pediatric relapsed and refractory acute lymphoblastic leukemia (ALL), which has poor outcomes. Here, we established 57 patient-derived xenografts (PDXs) in NOD.Cg-Prkdc

Indexed as

Biological Specimen BanksPrecursor Cell Lymphoblastic Leukemia-LymphomaAnimalsDisease Models, AnimalHeterograftsHumansJapanMiceMice, Inbred NODMice, SCIDXenograft Model Antitumor Assaysbiobankleukemiapediatricpreclinicalxenograft

Identifiers

PMID35879192
PMCPMC9633318
OpenAlexW4287832071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.